Multiple Myeloma Trial Results
Double Transplantation of One's Own Stem Cells Is Not Warranted for Multiple Myeloma
(Posted: 02/24/2009) - The addition of a second hematopoietic stem cell transplant procedure using one's own blood cells does not appear warranted in multiple myeloma, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
Drug Combination Shows Benefit in Relapsed/Refractory Multiple Myeloma
(Posted: 08/28/2007) - A new combination treatment should be another standard of care for patients with relapsed or refractory multiple myeloma, according to the Sept. 1, 2007, Journal of Clinical Oncology.
Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
(Posted: 04/04/2007) - Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.
Study Compares Stem Cell Transplant Treatments
(Posted: 03/21/2007) - Patients with newly diagnosed multiple myeloma who received a transplant of their own stem cells (autologous) and a second stem cell transplant from an HLA-matched sibling (allogeneic) had superior survival outcomes compared to patients who received two autologous stem cell transplants, according to the March 15, 2007, New England Journal of Medicine.
(Posted: 02/24/2009) - The addition of a second hematopoietic stem cell transplant procedure using one's own blood cells does not appear warranted in multiple myeloma, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
Drug Combination Shows Benefit in Relapsed/Refractory Multiple Myeloma
(Posted: 08/28/2007) - A new combination treatment should be another standard of care for patients with relapsed or refractory multiple myeloma, according to the Sept. 1, 2007, Journal of Clinical Oncology.
Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
(Posted: 04/04/2007) - Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.
Study Compares Stem Cell Transplant Treatments
(Posted: 03/21/2007) - Patients with newly diagnosed multiple myeloma who received a transplant of their own stem cells (autologous) and a second stem cell transplant from an HLA-matched sibling (allogeneic) had superior survival outcomes compared to patients who received two autologous stem cell transplants, according to the March 15, 2007, New England Journal of Medicine.
